GREENWICH, Conn.--(BUSINESS WIRE)--Med Opportunity Partners, LLC (“MEDOP”), a Greenwich CT-based private equity firm focused exclusively on the health care sector, announced today its acquisition of Ferro Pfanstiehl Laboratories, Inc., a global leader in cGMP carbohydrates and Active Pharmaceutical Ingredients (APIs), from Ferro Corporation. MEDOP, a strategic, operating-oriented investment firm, brings significant resources, pharmaceutical and biopharmaceutical relationships, and capital to fuel the Company’s growth. Ferro Pfanstiehl Laboratories, Inc. has been renamed Pfanstiehl, Inc. (“Pfanstiehl”), reflecting its rich history and reputation developed since the Company was founded in 1919. Pfanstiehl is a leading technology-based provider of specialized products and services for niche pharmaceutical and biotechnological applications. Cindy Kerker, President of Pfanstiehl, commented about the new partnership with MEDOP: “We are pleased to be backed by MEDOP as we enter a very exciting stage of our company’s history with an unprecedented opportunity for growth in the biopharmaceutical and pharmaceutical market place. Our ability to deliver quality, high purity excipients and APIs including cytotoxics to our customers should be enhanced by MEDOP and their strategic operating approach and financial resources.”
